SG11202004581PA - Partial agonists of interleukin-2 - Google Patents

Partial agonists of interleukin-2

Info

Publication number
SG11202004581PA
SG11202004581PA SG11202004581PA SG11202004581PA SG11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA SG 11202004581P A SG11202004581P A SG 11202004581PA
Authority
SG
Singapore
Prior art keywords
interleukin
partial agonists
agonists
partial
Prior art date
Application number
SG11202004581PA
Inventor
Kenan Christopher Garcia
Sonia S Majri
Caleb R Glassman
Leon Lih-Ren Su
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SG11202004581PA publication Critical patent/SG11202004581PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
SG11202004581PA 2017-11-21 2018-11-20 Partial agonists of interleukin-2 SG11202004581PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589497P 2017-11-21 2017-11-21
PCT/US2018/062122 WO2019104092A1 (en) 2017-11-21 2018-11-20 Partial agonists of interleukin-2

Publications (1)

Publication Number Publication Date
SG11202004581PA true SG11202004581PA (en) 2020-06-29

Family

ID=66631137

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004581PA SG11202004581PA (en) 2017-11-21 2018-11-20 Partial agonists of interleukin-2

Country Status (13)

Country Link
US (2) US20200299349A1 (en)
EP (1) EP3713592A4 (en)
JP (1) JP7464278B2 (en)
KR (1) KR20200086722A (en)
CN (1) CN111615396A (en)
AU (2) AU2018372167B2 (en)
BR (1) BR112020009920A2 (en)
CA (1) CA3082904A1 (en)
IL (1) IL274723A (en)
MX (1) MX2020005041A (en)
RU (1) RU2020120145A (en)
SG (1) SG11202004581PA (en)
WO (1) WO2019104092A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
BR112019024127A2 (en) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. TARGETED IMMUNOTOLERANCE
NZ761430A (en) 2017-08-03 2024-03-22 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
KR20220035333A (en) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 MADCAM Targeted Immune Tolerance
CN114853874A (en) * 2019-09-10 2022-08-05 中国医学科学院北京协和医院 Long-acting interleukin-2 of target regulatory T cell and application thereof in treating autoimmune disease
CN115023444A (en) 2019-12-20 2022-09-06 再生元制药公司 Novel IL2 agonists and methods of use thereof
CN115315436A (en) 2020-01-10 2022-11-08 明峰治疗股份公司 Modified IL-2 polypeptides and uses thereof
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
JP2023511274A (en) 2020-01-14 2023-03-17 シンセカイン インコーポレイテッド IL2 orthologs and usage
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN116916969A (en) * 2021-03-31 2023-10-20 韩美药品株式会社 Novel conjugates of immunostimulatory IL-2 analogues and methods of making the same
WO2023281480A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230250181A1 (en) 2021-07-09 2023-08-10 Bright Peak Therapeutics Ag Modified checkpoint inhibitors and uses thereof
KR20240040134A (en) 2021-07-09 2024-03-27 브라이트 피크 테라퓨틱스 아게 Antibody conjugates and their preparation
WO2023281482A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2788A1 (en) * 1998-05-15 2003-12-01 Bayer Ag Selective IL-2 agonists and antagonists.
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP2007527242A (en) * 2004-03-05 2007-09-27 カイロン コーポレーション In vitro test system for predicting patient tolerance of therapeutic agents
EP1846020B1 (en) * 2005-01-27 2013-08-21 Novartis Vaccines and Diagnostics, Inc. Methods for treating renal cell carcinoma
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
LT2637694T (en) * 2010-11-12 2021-05-25 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
JP6093712B2 (en) * 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Interleukin 2 superagonist and antagonist
MX370283B (en) * 2014-02-06 2019-12-09 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof.
US10150802B2 (en) * 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2

Also Published As

Publication number Publication date
RU2020120145A (en) 2021-12-22
IL274723A (en) 2020-07-30
CA3082904A1 (en) 2019-05-31
WO2019104092A1 (en) 2019-05-31
EP3713592A4 (en) 2022-01-12
AU2024200355A1 (en) 2024-03-21
AU2018372167B2 (en) 2023-12-07
EP3713592A1 (en) 2020-09-30
US20210269498A1 (en) 2021-09-02
JP2021508252A (en) 2021-03-04
AU2018372167A1 (en) 2020-06-11
JP7464278B2 (en) 2024-04-09
BR112020009920A2 (en) 2020-12-15
CN111615396A (en) 2020-09-01
US20200299349A1 (en) 2020-09-24
MX2020005041A (en) 2020-10-12
KR20200086722A (en) 2020-07-17

Similar Documents

Publication Publication Date Title
IL274723A (en) Partial agonists of interleukin-2
HK1258509A1 (en) Gitr agonists
EP3134102A4 (en) Superagonists, partial agonists and antagonists of interleukin-2
IL272888A (en) Novel uses of piperidinyl-indole derivatives
IL259947B (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
IL269196A (en) Novel inhibitors
GB201706477D0 (en) Modification of polypeptides
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
IL268731A (en) New uses of anti-sirpg antibodies
ZA202003267B (en) Novel combinations of defoliants
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL274627A (en) Solid state form of valbenazine
GB201719639D0 (en) Setection of biomarkers
HUE048481T2 (en) Compositions comprising substituted benzofuroquinolizine and alpha2-adrenergic agonists
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
AU201810507S (en) Part of refrigerator
AU201810512S (en) Part of refrigerator
PL3449931T3 (en) Use of cerebrolysin
IL269659B1 (en) Purification of an agent of interest
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
GB2557353B (en) Configuration of wireless-equipped devices
SG11202105136WA (en) Application of chidamide
GB201720445D0 (en) Use of TRPV1 agonists
GB201809911D0 (en) Use of trpv1 agonists
GB201620933D0 (en) Use of TRPV1 agonists